Bombesin inhibits growth hormone response to insulin-induced hypoglycemia in humans.
Intravenous administration of bombesin (5 ng/kg/min X 2.5 h) significantly reduced growth hormone (GH) response to insulin-induced (0.15 U/kg, i.v.) hypoglycemia in 8 male volunteers without affecting its basal plasma levels. These data, together with the presence of bombesin-like immunoreactivity in the human brain, suggest that--as in experimental animals--this neurogastrointestinal peptide may be of physiological significance in the control of GH secretion also in man.